Certolizumab pegol for the treatment of psoriasis. Campanati A, Benfaremo D, Luchetti MM, Ganzetti G, Gabrielli A, Offidani A. Expert Opin Biol Ther. 2017 Feb 6:1-8. doi: 10.1080/14712598.2017.1283401. [Epub ahead of print]

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Togo O, Okada T, van der Heijde D, Miyasaka N, Koike T. Ann Rheum Dis. 2017 Feb 2. pii: annrheumdis-2016-210246. doi: 10.1136/annrheumdis-2016-210246.

Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases. Lee JU, Shin W, Son JY, Yoo KY, Heo YS. Int J Mol Sci. 2017 Jan 23;18(1). pii: E228. doi: 10.3390/ijms18010228.